ID

38231

Beschreibung

A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours; ODM derived from: https://clinicaltrials.gov/show/NCT01493336

Link

https://clinicaltrials.gov/show/NCT01493336

Stichworte

  1. 30.09.19 30.09.19 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

30. September 2019

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Breast Cancer, Colorectal Cancer NCT01493336

Eligibility Breast Cancer, Colorectal Cancer NCT01493336

Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
adult patients,>/= 18 years of age
Beschreibung

Adult | Age

Datentyp

boolean

Alias
UMLS CUI [1]
C0001675
UMLS CUI [2]
C0001779
histological/cytological confirmation of colorectal or breast cancer
Beschreibung

Colorectal Carcinoma | Breast Carcinoma

Datentyp

boolean

Alias
UMLS CUI [1]
C0009402
UMLS CUI [2]
C0678222
patient is ambulatory and has a karnofsky performance status of > 70%
Beschreibung

Patient Ambulatory | Karnofsky Performance Status

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0030705
UMLS CUI [1,2]
C0439841
UMLS CUI [2]
C0206065
body surface area between 1.5 and 2.0 m2
Beschreibung

Body Surface Area

Datentyp

boolean

Alias
UMLS CUI [1]
C0005902
either:
Beschreibung

Either

Datentyp

boolean

Alias
UMLS CUI [1]
C3844638
due to receive xeloda as monotherapy or as combination therapy as per their treating physician's treatment plan, or
Beschreibung

Etiology | Xeloda | Combined Modality Therapy

Datentyp

boolean

Alias
UMLS CUI [1]
C0015127
UMLS CUI [2]
C0724419
UMLS CUI [3]
C0009429
currently receiving xeloda monotherapy and in the investigator's opinion able to tolerate study drug dose on day 1 and day 2
Beschreibung

Xeloda | Ability Receive Investigational New Drugs

Datentyp

boolean

Alias
UMLS CUI [1]
C0724419
UMLS CUI [2,1]
C0085732
UMLS CUI [2,2]
C1514756
UMLS CUI [2,3]
C0013230
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
any contraindication to xeloda
Beschreibung

Medical contraindication Xeloda

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1301624
UMLS CUI [1,2]
C0724419
received xeloda in the 6 days prior to day 1
Beschreibung

Xeloda Received Recently

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0724419
UMLS CUI [1,2]
C1514756
UMLS CUI [1,3]
C0332185
subjects with organ allografts (other than autologous bone marrow transplant after high dose chemotherapy)
Beschreibung

Organ allografts | Exception Autologous bone marrow transplant Post High-dose chemotherapy

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0178784
UMLS CUI [1,2]
C0040739
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0194037
UMLS CUI [2,3]
C0687676
UMLS CUI [2,4]
C1328050
renal impairment
Beschreibung

Renal Insufficiency

Datentyp

boolean

Alias
UMLS CUI [1]
C1565489
pregnant or lactating females
Beschreibung

Pregnancy | Breast Feeding

Datentyp

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
participation in an investigational drug study within 28 days prior to screening
Beschreibung

Study Subject Participation Status | Investigational New Drugs

Datentyp

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0013230
lack of physical integrity of the upper gastrointestinal tract, or clinically significant malabsorption syndrome
Beschreibung

Lacking Integrity Upper Gastrointestinal Tract | Malabsorption Syndrome

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0332268
UMLS CUI [1,2]
C1947912
UMLS CUI [1,3]
C3203348
UMLS CUI [2]
C0024523
serious uncontrolled intercurrent infections
Beschreibung

Communicable Diseases Serious Uncontrolled

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0009450
UMLS CUI [1,2]
C0205404
UMLS CUI [1,3]
C0205318
history of clinically significant coronary artery disease
Beschreibung

Coronary Artery Disease

Datentyp

boolean

Alias
UMLS CUI [1]
C1956346
concomitant treatment with warfarin
Beschreibung

Warfarin therapy

Datentyp

boolean

Alias
UMLS CUI [1]
C4303340
known dihydropyrimidine dehydrogenase deficiency
Beschreibung

Dihydropyrimidine Dehydrogenase Deficiency

Datentyp

boolean

Alias
UMLS CUI [1]
C1959620

Ähnliche Modelle

Eligibility Breast Cancer, Colorectal Cancer NCT01493336

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Adult | Age
Item
adult patients,>/= 18 years of age
boolean
C0001675 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Colorectal Carcinoma | Breast Carcinoma
Item
histological/cytological confirmation of colorectal or breast cancer
boolean
C0009402 (UMLS CUI [1])
C0678222 (UMLS CUI [2])
Patient Ambulatory | Karnofsky Performance Status
Item
patient is ambulatory and has a karnofsky performance status of > 70%
boolean
C0030705 (UMLS CUI [1,1])
C0439841 (UMLS CUI [1,2])
C0206065 (UMLS CUI [2])
Body Surface Area
Item
body surface area between 1.5 and 2.0 m2
boolean
C0005902 (UMLS CUI [1])
Either
Item
either:
boolean
C3844638 (UMLS CUI [1])
Etiology | Xeloda | Combined Modality Therapy
Item
due to receive xeloda as monotherapy or as combination therapy as per their treating physician's treatment plan, or
boolean
C0015127 (UMLS CUI [1])
C0724419 (UMLS CUI [2])
C0009429 (UMLS CUI [3])
Xeloda | Ability Receive Investigational New Drugs
Item
currently receiving xeloda monotherapy and in the investigator's opinion able to tolerate study drug dose on day 1 and day 2
boolean
C0724419 (UMLS CUI [1])
C0085732 (UMLS CUI [2,1])
C1514756 (UMLS CUI [2,2])
C0013230 (UMLS CUI [2,3])
Item Group
C0680251 (UMLS CUI)
Medical contraindication Xeloda
Item
any contraindication to xeloda
boolean
C1301624 (UMLS CUI [1,1])
C0724419 (UMLS CUI [1,2])
Xeloda Received Recently
Item
received xeloda in the 6 days prior to day 1
boolean
C0724419 (UMLS CUI [1,1])
C1514756 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
Organ allografts | Exception Autologous bone marrow transplant Post High-dose chemotherapy
Item
subjects with organ allografts (other than autologous bone marrow transplant after high dose chemotherapy)
boolean
C0178784 (UMLS CUI [1,1])
C0040739 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0194037 (UMLS CUI [2,2])
C0687676 (UMLS CUI [2,3])
C1328050 (UMLS CUI [2,4])
Renal Insufficiency
Item
renal impairment
boolean
C1565489 (UMLS CUI [1])
Pregnancy | Breast Feeding
Item
pregnant or lactating females
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Study Subject Participation Status | Investigational New Drugs
Item
participation in an investigational drug study within 28 days prior to screening
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Lacking Integrity Upper Gastrointestinal Tract | Malabsorption Syndrome
Item
lack of physical integrity of the upper gastrointestinal tract, or clinically significant malabsorption syndrome
boolean
C0332268 (UMLS CUI [1,1])
C1947912 (UMLS CUI [1,2])
C3203348 (UMLS CUI [1,3])
C0024523 (UMLS CUI [2])
Communicable Diseases Serious Uncontrolled
Item
serious uncontrolled intercurrent infections
boolean
C0009450 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0205318 (UMLS CUI [1,3])
Coronary Artery Disease
Item
history of clinically significant coronary artery disease
boolean
C1956346 (UMLS CUI [1])
Warfarin therapy
Item
concomitant treatment with warfarin
boolean
C4303340 (UMLS CUI [1])
Dihydropyrimidine Dehydrogenase Deficiency
Item
known dihydropyrimidine dehydrogenase deficiency
boolean
C1959620 (UMLS CUI [1])

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video